Jason Saliba

Jason Saliba

Auto-generated profile, based on publicly available information

Jason Saliba

Department of Medicine, Washington University in St Louis School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JPJoanna Pierro
Joanna Pierro
JSJason Saliba
Jason Saliba
SNSonali Narang
Sonali Narang
GSGunjan Sethia
Gunjan Sethia
SFShella Saint Fleur-Lominy
Shella Saint Fleur-Lominy
WCWilliam L Carroll
William L Carroll
The NSD2 p.E1099K (EK) mutation is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate clonal expansion, we engineered B-precursor ALL (B-ALL) cell lines (Reh, 697) to overexpress wildtype (WT) and EK NSD2, but observed no differences in proliferation, clonal growth, or chemosensitivity. To address whether NSD2 EK acts collaboratively with other pathways, we used short hairpin RNAs to knockdown expression of NSD2 in B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM). Knockdown resulted in decreased proliferation in all lines, decreased clonal growth in RCH-ACV, and increased sensitivity to cytotoxic chemotherapeutic agents, although the pattern of drug sensitivity varied among cell lines implying that the oncogenic properties of NSD2 mutations are likely cell context specific and rely on cooperative pathways. Knockdown of both Type II and REIIBP EK isoforms had a greater impact than knockdown of Type II alone, suggesting that both SET containing EK isoforms contribute to phenotypic changes driving relapse. Furthermore, in vivo models using both cell lines and patient samples revealed dramatically enhanced proliferation of NSD2 EK compared with WT and reduced sensitivity to 6-mercaptopurine in the relapse sample relative to diagnosis. Finally, EK-mediated changes in chromatin state and transcriptional output differed dramatically among cell lines further supporting a cell context–specific role of NSD2 EK. These results demonstrate a unique role of NSD2 EK in mediating clonal fitness through pleiotropic mechanisms dependent on the genetic and epigenetic landscape. Implications: NSD2 EK mutation leads to drug resistance and a clonal advantage in childhood B-ALL.

16 March 2022 in Cancer Genetics
Verified
Journal Article
Closed access
JSJason Saliba
Jason Saliba
ACAlanna J. Church
Alanna J. Church
SRShruti Rao
Shruti Rao
ADArpad Danos
Arpad Danos
LFLarissa V. Furtado
Larissa V. Furtado
ARAngshumoy Roy
Angshumoy Roy

25 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SNSonali Narang
Sonali Narang
NENikki Evensen
Nikki Evensen
JSJason Saliba
Jason Saliba
JPJoanna Pierro
Joanna Pierro
MLMignon L. Loh
Mignon L. Loh
WCWilliam L Carroll
William L Carroll
The NSD2 p.E1099K (EK) mutation has been shown to be enriched in patients with relapsed ALL and found to play a role in clonal fitness dependent on the underlying genetic/epigenetic landscape of the cells. To uncover 3D chromatin architecture-related mechanisms underlying drug resistance, we systematically integrated Hi-C, ATAC-seq, RNA-seq and ChIP-seq data from three B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM) and assessed changes upon knockdown. NSD2 knockdown revealed widespread remodeling of the 3D genome, specifically in terms of compartmentalization. Systematic integration of these datasets revealed significant switches in A/B compartments with a strong bias towards B compartments upon knockdown, suggesting that NSD2 EK plays a prominent role in maintaining A compartments through enrichment of H3K36me2 epigenetic marks. In contrast, we identified few changes in intra-TAD activity suggesting that the NSD2 EK impacts transcriptional changes through a remarkable dependence on compartmentalization. Furthermore, EK-mediated reorganization of compartments highlights the existence of a common core of compacting loci shared across the three cell lines that explain previously described phenotypes as well as serve as targets for therapeutic intervention. This study offers a novel mechanism by which NSD2 EK drives clonal evolution and drug resistance.

15 September 2025 in bioRxiv
Verified
Preprint
Open access
CRCaralyn Reisle
Caralyn Reisle
CGCameron J. Grisdale
Cameron J. Grisdale
KKKilannin Krysiak
Kilannin Krysiak
ADArpad M. Danos
Arpad M. Danos
MKMariam Khanfar
Mariam Khanfar
SJSteven Jones
Steven Jones
Accurate interpretation of genomic variants is critical for precision oncology but remains slow and dependent on specialized expertise. Public knowledgebases such as the Clinical Interpretation of Variants in Cancer (CIViC) help by curating literature-backed variant interpretations in a structured form, yet verification and review have become major bottlenecks. To address this, we developed CIViC-Fact, a benchmark dataset and pipeline for testing automated systems that verify the accuracy of cancer variant claims. CIViC-Fact links structured claims to sentence-level supporting or refuting evidence from full-text articles, and includes expert annotations and explanations. We evaluated multiple language models. Proprietary models performed well without training, but a smaller open-source model, fine-tuned on CIViC-Fact, achieved the highest accuracy (89%). Applying our fact-checking pipeline to real CIViC entries showed that reviewing less than 20% of content, focusing on flagged entries, would be sufficient to catch over half of all errors. This AI-assisted triage greatly accelerates the review process without replacing or reducing expert insight, ensuring that existing careful oversight remains in place while curators can work more efficiently. CIViC-Fact provides a realistic, high-consequence framework for biomedical fact-checking and a path toward more rigorous and efficient knowledgebase curation.

3 April 2023
Verified
Other
Open access
JPJoanna Pierro
Joanna Pierro
JSJason Saliba
Jason Saliba
SNSonali Narang
Sonali Narang
GSGunjan Sethia
Gunjan Sethia
SFShella Saint Fleur-Lominy
Shella Saint Fleur-Lominy
WCWilliam L. Carroll
William L. Carroll
Supplementary materials and methods and supplementary figure legends.

3 April 2023
Verified
Other
Open access
JPJoanna Pierro
Joanna Pierro
JSJason Saliba
Jason Saliba
SNSonali Narang
Sonali Narang
GSGunjan Sethia
Gunjan Sethia
SFShella Saint Fleur-Lominy
Shella Saint Fleur-Lominy
WCWilliam L. Carroll
William L. Carroll